Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve
To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.
EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette...
EuMentis plans to initiate Phase 2 clinical trials with EM-113 in autism spectrum disorder (ASD) and EM-221 in Tourette syndrome (TS) in 2nd half of this year
EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury
Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia and plans to advance its lead NMDA receptor antagonist candidate for TBI to the clinic in 2024.
InDevR Raises $9 Mil in Series B Financing
Kathy Rowlen, CEO at InDevR, said: “I am grateful for the opportunity to continue our successful partnership with Adjuvant Capital, and to work with the talented team at bioMérieux. The expertise at bioMérieux, combined with our innovation engine, will ensure that our CQA/QC tools are backed by a trusted partner who understands the needs of the highly regulated pharma industry.”
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers. It plays a crucial role in tumor survival and spread. ISA103 was developed using the company’s proprietary Synthetic Long Peptide (SLP®) technology, designed to fully harness and direct the body’s defense mechanisms towards fighting the disease. It contains multiple long peptides spanning the most immunogenic regions of the PRAME protein.
iOnctura Awarded EUR17.5 Mil Funding from the EIC Accelerator for Clinical Development of Novel Pancreatic Cancer Therapy
On 8 December 2022 iOnctura announced the first patient was dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.